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Introduction
Cystic fibrosis (CF) is a multi-organ disease, characterized 
by chronic systemic inflammation and high-energy expendi-
ture. Exocrine pancreatic insufficiency often develops in the 
first year of life. Malnutrition and low body weight are com-
mon clinical findings in CF despite enzyme replacement ther-
apy. Endocrine pancreas insufficiency appears later in course 
of disease. However, improved symptomatic treatment reg-
imens and better outcomes following lung transplantation 
have contributed to an improved overall life expectancy in 
patients with CF over the last years [1]; Thus, disorders of 
glucose homeostasis increasingly emerge in clinical practice. 
Up to half of adult patients with CF have CF related diabetes 
(CFRD). CFRD is related to increasing age, duration of exocrine 
pancreatic failure, and the Phe508del homozygous state. In 
Research Article
Abstract
Aim: The oral glucose tolerance test (OGTT) is part of the routine management and readily detects impaired insulin 
secretion in the majority of adult patients with cystic fibrosis (CF). To assess an activity of endogeneous insulin on adipose 
tissue in these patients, we analyzed serum levels of insulin and free fatty acids (FFA) in response to oral glucose since 
glucose-induced insulin decreases FFA and thus, suppression of FFA reflects an insulin effect on adipose tissue.
Methods: Adult patients with end-stage CF lung disease without known dysglycemic disorder and a control group of 
healthy subjects were included. We assessed levels of two adipokines, adiponectin and leptin, and suppression of FFA 
during OGTT. Insulin secretion was estimated by the insulinogenic index (IGI), and whole body and adipose tissue insulin 
sensitivity by the indices ISI
comp 
and ISIfat, respectively.
Results: OGTTs were performed in 39 patients and 23 controls. Plasma glucose at 2h was higher and IGI was lower in 
patients with CF than in controls. ISI
comp
 and ISIfat were similar in patients with CF and in controls. During OGTT, FFA 
decreased to a comparable extent in both groups. Leptin was lower whereas total adiponectin tended to be higher and 
its HMW form was significantly higher in patients with CF than in controls.
Conclusion: Residual insulin (in face of apparently normal insulin sensitivity and increased energy expenditure and – 
possibly adiponectin-enhanced – FFA oxidation) appears to be sufficient for maintaining FFA homeostasis in patients with 
advanced CF lung disease. 
Keywords
Oral glucose tolerance test, Cystic fibrosis related diabetes, Insulin sensitivity, Free fatty acids, Adiponectin, Leptin
Abbreviations
A1c: Glycated Haemoglobin; AUC: Area Under Curve; CF: Cystic Fibrosis; CFRD: Cystic Fibrosis Related Diabetes; CFTR: 
Cystic Fibrosis Transmembrane Conductance Regulator; FEV1: Forced Expiratory Volume in 1 Second; GH: Growth 
Hormone; h: Hours; HMW: High Molecular Weight; IGF-1: Insulin-Like Growth Factor-1; IGI: Insulinogenic Index; IGT: 
Impaired Glucose Tolerance; INDET: Indeterminate Glucose Tolerance; IQR: Interquartile Range; ISI
comp
: Whole Body 
Insulin Sensitivity Index; ISIfat: Adipose Tissue Insulin Sensitivity Index; NGT: Normal Glucose Tolerance; OGT: Oral Glucose 
Tolerance; OGTT: Oral Glucose Tolerance Test; PG: Plasma Glucose U/V: Unit/Volume
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fasting PG ≥ 7 mmol/l, insulin treatment, corticosteroid ther-
apy and BMI ≥ 30 kg/m2. We used control subjects who had 
an OGTT for other reasons (i.e., diagnostic evaluation of a 
potential hypoglycemic disorder, or exclusion of acromega-
ly) and in whom a dysglycemic disorder was excluded [17]. 
Study patients and controls were matched for age and gen-
der. The study was approved by the Local Ethics Committee 
and written informed consent was obtained.
CF status
All patients with CF undergoing evaluation for lung trans-
plantation had forced expiratory volume in 1 second (FEV1) 
measured by spirometry and their body weight by an elec-
tronic scale. All data were collected within 1 week of OGTT. 
CF genotype status was retrieved from patients’ records. 
Laboratory values and oral glucose tolerance 
test
All patients and the control group had laboratory analysis 
as described below and underwent a standard 75 g OGTT. In 
the morning after an overnight fast, a peripheral intravenous 
line was placed into the antecubital vein of all subjects fol-
lowed by the ingestion a solution with 75 g glucose. Blood 
samples for glucose, insulin and FFA were obtained at base-
line (mean of two samples, taken 15 min and immediately 
before) as well as 30, 60, 90, and 120 min after glucose load. 
According to the results of the OGTT, study patients were 
divided in two groups: one group with CFRD and the other 
without CFRD. CFRD was diagnosed when glucose readings 
120 minutes after glucose load were ≥ 11.1 mmol/l.
Laboratory measurements
Venous PG was measured by the hexokinase method 
(Beckman Analyzer; Fullerton, CA, USA), serum insulin by sol-
id phase radioimmunoassay (CIS Bio International, Oris Indus-
tries, Gif-Sur-Yvette, France) and FFA by an enzymatic end-
point calorimetric assay (Wako Diagnostics, 1600 Bellwood 
Road, Richond, VA 23237-1326, USA). Glycated Haemoglobin 
(A1c) was measured by immunoturbidimetric method in EDTA 
blood samples. Adiponectin was measured by EIA (R&D Sys-
tems, Inc., 614 McKinley Place NE, Minneapolis, MN 55413) 
and its high molecular weight (HMW) multimer form by ELISA 
(ALPCO, 26-G Keewaydin Drive, Salem, NH 03079). Leptin was 
measured by Human Leptin ELISA Kit (Cat. EZHL-80SK, EMD 
Millipore Corporation, St. Charles, Missouri 63304 USA).
β-cell function and insulin sensitivity indices
To estimate β-cell function, the insulinogenic index (IGI) was 
calculated as proposed by Wareham, i.e., as the ratio of the in-
crement of serum insulin (between 0 and 30 min) to PG at 30 
min after the glucose load [18]. Whole body insulin sensitivity in-
dex (ISI
comp
) was calculated by data obtained during the OGTT ac-
cording to Matsuda and DeFronzo: ISI
comp
 = 10,000/square root 
of [(mean plasma insulin × mean glucose during OGTT) × (fasting 
PG × fasting plasma insulin)]. Insulin sensitivity of adipose tissue 
(ISIfat) was estimated as proposed by Belfiore [10]: ISIfat = 2/[(area 
under curve (AUC)
INSp 
× AUC
FFAp
) + 1], where AUC
INSp
 and AUC
FFAp
 
represent insulinemic and FFA areas under curve (AUC) during 
addition, oral glucose tolerance test (OGTT) detects impaired 
glucose tolerance (IGT; Fasting, ≤ 7.0 mmol/l and 2h plasma 
glucose (2hPG), ≥ 7.8 mmol/l and ≤ 11.0 mmol/l) or indeter-
minate glucose tolerance (INDET; fasting, ≤ 7.0 mmol/l and 
2hPG, ≤ 7.7 mmol/l, but 1hPG ≥ 11.1 mmol/l) in another sub-
stantial proportion of patients [2,3]. At our centre, the ma-
jority of patients (75%) are diagnosed with CFRD at the time 
of evaluation and listing for lung transplantation [4]. Inflam-
matory pancreatic tissue destruction and subsequent islet 
cell loss is probably a main cause of CFRD and impaired glu-
cose tolerance [5,6]. While the decreased insulin secretion is 
well accepted in the pathogenesis of CFRD, the role of insulin 
resistance is less clear, and data are conflicting [6].
Patients with CFRD rarely present with ketoacidosis, sug-
gesting that a complete lack of insulin action is rather excep-
tional in patients with CF. Adipose tissue is often reduced 
in patients with CF, and clearance of energy-providing sub-
strates such as glucose and FFA is high even if ambient insulin 
concentrations are relatively low, i.e. non-insulin-mediated 
glucose and FFA disposal may be increased. Patients with CF 
have increased resting energy expenditure, related to the CF 
transmembrane conductance regulator (CFTR) gene, pan-
creatic and lung function, and inflammatory and nutritional 
status [7,8]. FFA release from stored triglycerides (lipolysis) 
is very sensitive to suppression by insulin, and in most condi-
tions, insulin appears to control FFA levels by reducing their 
endogenous appearance rate [9]. Epidemiological studies 
have linked increased FFA levels to obesity, insulin resistance 
and type-2 diabetes. The adipose tissue insulin sensitivity in-
dex as proposed by Belfiore (ISIfat) is based on suppression of 
FFA in an OGTT by endogeneous insulin; and the ISIfat was de-
creased in such patients [10,11]. However, studies applying 
this method in patients with CF are lacking. 
Adiponectin is by far the most abundant adipokine, it has 
anti-inflammatory and insulin-sensitizing properties. It circu-
lates in several forms; the most abundant are high molecu-
lar-weight (HMW) multimers. In patients with obesity, insulin 
resistance, hyperinsulinemia, and type 2 diabetes, the levels 
of adiponectin and specifically its HMW form are reduced 
[12,13]. Adiponectin is elevated in patients with type 1 diabe-
tes and in patients with anorexia nervosa [14-16].
Leptin is predominantly secreted from adipocytes; its 
serum levels usually correlate positively with fat mass and 
body weight. Therefore, elevated serum leptin levels are 
common in obesity and possibly thereby associated with 
insulin resistance and hyperinsulinemia. In contrast, anorectic 
and underweight patients show low leptin levels [15]. 
The main goal of our study was to assess suppression of 
FFA during OGTT; moreover, we measured adiponectin and 
leptin in patients with CF evaluated for lung transplantation. 
Methods
Subjects
Over a 10-year period, we recruited consecutive patients 
with CF undergoing evaluation for lung transplantation. In-
clusion criteria were age ≥ 18 years and agreement to par-
ticipate in the study. Exclusion criteria were known previous 
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significant.
Results 
Characteristics of patients with CF
Data are shown in Table 1. Thirty nine patients with CF 
(21 women; median age 24 (IQR 21-35) y and 23 controls (12 
women; median age 31 (IQR 23-35) y were included in the 
study. Nineteen patients were homozygous and 14 were het-
erozygous for Phe508del, respectively; six patients had other 
CF-defining genotypes. The CF-group was fairly homogenous 
OGTT of the person under study divided by the mean inuline-
mic or FFA AUC of control group. AUC was calculated as unit/
volume (U/V) × min-1 = [(U/V
0’
 + U/V
30’
) × 30/2)] + [(U/V
30’
 + U/V
60’
) 
× 30/2)] + [(U/V
60’
 + U/V
90’
) × 30/2)] + [(U/V
90’
 + U/V
120’
) × 30/2)].
Statistics
Data are presented as median and interquartile range 
(IQR) since some of the values were not normally distributed. 
Accordingly, the statistical evaluation for potential differenc-
es between the groups of patients and controls was done by 
unpaired Wilcoxon rank-sum test. p < 0.05 was considered 
Table 1: Characteristics of patients with CF and controls.
 Controls CF total CF no CFRD CF CFRD
Number (n) 23 39 25 14
Men/Women (n) 11/12 18/21 13/12 5/9 
Age (y) 31 (23; 35) 24 (21; 35) 23 (21; 34)* 26 (23; 38)
CFTR genotype° 0/0/0/23 19/14/6/0 12/8/5/0 7/6/1/0
BMI (kg/m2) 22.0 (20.7; 24.8) 18.0 (16.8; 19.7)**** 18.4 (17.2; 19.8)**** 17.8 (15.5; 19.8)****
FEV1 (%) not analyzed 28 (21; 38) 32 (26; 46) 23 (19; 31)
A1c (%)1 5.4 (5.3; 5.6) 6.1 (5.9; 6.3)**** 6.0 (5.8; 6.2)**** 6.2 (6.0; 6.6)****
A1c (mmol/mol)1 36 (34; 38) 43 (41; 45)**** 42 (40; 44)**** 44 (42; 49)****
Glu0' (mmol/l) 4.5 (4.2; 4.7) 4.7 (4.5; 5.3)
* 4.6 (4.5; 5.1) 5.2 (4.6; 5.9)**
Albumin (g/l)2 41 (39; 45) 38 (35; 41)** 38 (35; 41)* 38 (35; 40)**
CRP (mg/l)3 0 (0; 2) 11 (5; 30)**** 12 (5; 38)**** 7 (4; 22)***
Data are expressed as median (IQR).   
°Phe508del homozygous/heterozygous/other genotype/not analysed.  
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 for the comparison controls vs. CF total/CF no CFRD/CF CFRD.
1: Measured in 13 of 23 controls; 2: Measured in 19 of 23 controls and 38 of 39 CF patients; 3: Measured in 21 of 23 controls.
Table 2: Adiponectin and leptin; Glucose, insulin and free fatty acids during OGTT and derived indices. 
 Controls CF total CF no CFRD CF CFRD
Leptin (ng/ml) 6.1 (2.8; 12.8) 1.9 (0.5; 3.6)** 1.2 (0.6; 3.2)** 2.1 (0.5; 7.2)*
Adiponectin (μg/ml) 7.4 (4.8; 11.9) 9.4 (8.1; 12.6) 9.1 (7.2; 12.3) 11.1 (9.0; 12.9)
HMW adiponectin (%)1 40 (27; 44) 52 (46; 58)*** 48 (45; 54)** 58 (50; 62)**
Glu0' (mmol/l) 4.5 (4.2; 4.7) 4.7 (4.5; 5.3)
* 4.6 (4.5; 5.1) 5.2 (4.6; 5.9)**
Glu120' (mmol/l) 5.7 (4.4; 7.0) 9.4 (7.0; 13.0)
**** 7.6 (4.8; 9.2)* 14.0 (13.0; 16.0)****
AUC glu (mmol/l × 120 min) 797 (762; 890) 1188 (936; 1302)**** 995 (849; 1172)*** 1412 (1264; 1651)****
Ins0' (pmol/l) 100 (82; 136) 107 (79; 129) 109 (81; 129) 86 (57; 149)
Ins120' (pmol/l) 377 (206; 646) 349 (276; 632) 343 (234; 658) 434 (296; 612)
AUC ins (pmol/l × 120 min) 57060 (42450; 69105) 38340 (31560; 56295)** 48990 (36270; 64905) 31680 (22283; 36780)***
FFA0' (mmol/l) 0.63 (0.29; 0.97) 0.53 (0.35; 0.81) 0.49 (0.33; 0.65) 0.77 (0.42; 1.00)
FFA120' (mmol/l) 0.09 (0.05; 0.20) 0.13 (0.05; 0.19) 0.13 (0.07; 0.18) 0.14 (0.04; 0.20)
AUC FFA (mmol/l × 120 min) 29.7 (11.9; 50.3) 31.7 (20.1; 42.0) 23.9 (19.5; 36.5) 37.4 (28.1; 53.1)
IGIW (∆I0-30'/G30'; pM/mM) 58.3 (46.9; 81.3) 14.5 (7.4; 27.7)
**** 21.4 (14.2; 31.0)**** 7.3 (4.8; 10.2)****
ISIcomp (1/mMpM) 9.2 (7.0; 11.0) 8.5 (6.4; 11.4) 8.0 (6.7; 10.5) 9.3 (5.7; 12.0)
ISIfat (index) 1.20 (0.80; 1.50) 1.20 (1.10; 1.40) 1.20 (1.05; 1.45) 1.25 (1.08; 1.35)
Data are presented as median (IQR).
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 for the comparison controls vs. CF total/CF no CFRD/CF CFRD.
1: measured in 15 of 23 controls and 35 of 39 CF patients.
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0.05) in patients without CFRD and much higher (p < 0.0001) 
in those with CFRD (by definition, ≥ 11.1 mmol/l). A new diag-
nosis of CFRD was made in 14 (36%) patients. In addition, 10 
(26%) patients with CF had IGT, and 4 (10%) INDET (both sub-
groups included in the 25 CF no CFRD in Table 1 and Figure 1).
Insulin, OGTT-derived indices and FFA suppres-
sion
Data are shown in Table 2 and Figure 1. Insulin measured 
before and 2 hours after glucose intake was similar in 
patients with CF and controls. However, in patients with CF 
the insulin peak was delayed, leading to a significantly lower 
IGI in patients with CF compared to controls. The decrease 
in IGI was more pronounced in patients with CFRD, and 
less marked (intermediate) in those with IGT and INDET. Of 
note, patients without CFRD but especially those with IGT 
or INDET also showed delayed insulin secretion with a peak 
after 90 minutes, having a low IGI but normal AUC of insulin. 
In contrast to the significantly decreased IGI in CF patients, 
ISI
comp
 and ISIfat were similar in patients in controls and CF-
patients (and independent whether CFRD was diagnosed or 
not). Despite lower and delayed insulin secretion (resulting 
in higher glucose values) in patients with CF, FFA decreased 
to a similar extent as in controls, irrespectively of whether 
subjects had CFRD or not.
Adiponectin and Leptin
Data are shown in Table 2 and Figure 2. Total adiponectin 
was similar in patients with CF and controls (with a trend for 
higher values in the former group), and HMW-adiponectin 
was significantly higher in patients with CF than in controls. 
Leptin was significantly lower in patients with CF than in 
controls. 
Discussion
Our results confirm previous reports on high diabetes 
incidence in patients with CF, and the low IGI is in line with 
the generally accepted view of impaired insulin secretion as 
an important pathogenic mechanism in CFRD. Nevertheless, 
oral glucose suppressed FFA to a similar extent in patients 
with CF compared to controls.
Patients with type 2 diabetes have impaired insulin-
mediated FFA suppression by OGTT, and therefore, a low 
ISIfat [10]. Carlson, et al. reported on a small subgroup of 
elderly patients with isolated post challenge hyperglycemia 
(i.e., normal fasting and diabetic 2hPG values), similar to the 
majority of our CF patients. This subgroup was characterized 
by increased FFA levels (basal and during OGTT), despite 
increased insulin levels at 2h [19]. The authors concluded 
that elevated FFA not only reflect but also contribute to 
insulin resistance and elevated 2hPG levels. Although not 
consistently insulin resistant as most obese patients with 
type 2 diabetes, fluctuating insulin sensitivity contributes to 
changes in glucose tolerance of patients with CF and normal 
glucose tolerance (NGT), INDET or IGT; this may well account 
for the characteristically high variability in oral glucose 
tolerance (OGT) in patients with CF [2,20,21]. It is conceivable 
that in patients with a given reduced insulin secretion and 
as all patients were undergoing lung transplantation assess-
ment, implicating that all of them were suffering from severe 
lung disease, dominating their markedly reduced health sta-
tus. Their median FEV1 was 28 (IQR 21-38)%. BMI was signif-
icantly lower, fasting PG was borderline and A1c on average 
markedly higher, albumin was lower and CRP higher in pa-
tients with CF than in controls.
Plasma glucose during OGTT
Data are shown in Table 2 and Figure 1. Fasting PG was 
similar in patients without CFRD and controls and slighly high-
er in patients with CFRD. PG 2 hours after glucose intake was 
much higher in patients with CF than in controls. Compared 
to control group, the 2hPG was only slightly increased (p < 
         
Figure 1: Glucose, insulin and free fatty acid concentrations 
during OGTT.
Mean values and 95% CI are shown. 
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can change dramatically within a relatively short period 
in CFRD patients, an observation that illustrates again the 
contribution of insulin sensitivity. Using indices (ISI
comp
 and 
ISIfat) derived from endogenous insulin values; we found no 
evidence for insulin resistance in our patients with CF.
Milunsky, et al. [22] analyzed FFA during OGTT in children 
with CF several decades ago. Their (mostly pre-pubertal) pa-
tients had slightly elevated glucose values, marked insulin-
openia, and increased growth hormone (GH) levels. Increased 
GH secretion is presumably a consequence of decreased in-
sulin-like growth factor-1 (IGF-1) as expected in CF patients 
(and found in our CF patients, not shown) and favours insu-
lin resistance, lipolysis and an increase in FFA. Nevertheless, 
FFA levels in their patients with CF were similar to those of 
controls [22]. Consistent with these findings, Hammana, et al. 
[23] found normal FFA suppression during OGTTs in patients 
with CF under conditions reflecting insulin action of everyday 
life conditions. The authors concluded that insulin levels re-
mained sufficiently high to inhibit lipolysis and to stimulate 
lipogenesis, showing a striking dichotomy between postpran-
dial glucose and FFA/lipid control in patients with CF [23]. The 
number of patients in the Hammana, et al. [23] study (16 per 
group) was relatively low, not including subjects more severe-
ly affected by their lung disease. In our study, we included 
many patients with more advanced CF lung disease, very se-
vere insulin deficiency and markedly impaired glucose toler-
ance, yet, we reach the same conclusions as Hammana, et al. 
[23], namely that CF patients show abnormal post challenge 
glucose but not FFA excursions.
To date, adiponectin may also be high in patients with 
CF and insulinopenia but data have not been consistent. El-
evated adiponectin levels have been found in some [24,25], 
but not all [26] studies, possibly related to inflammation, 
chronic energy deficit and wasting. According to our results, 
HMW-adiponectin is often increased in severely ill patients. 
Hyperadiponectinemia has been shown to be associated with 
underweight and malnutrition and normalizes after refeed-
ing; particularly HMW-adiponectin is increased in patients 
with anorexia [15]. It remains unclear whether insulin can 
downregulate adiponectin in patients with anorexia and in 
patients with CF. Furthermore, it is unknown whether high 
adiponectin levels contribute to or merely reflect wasting. 
According to studies in animals, adiponectin acts in the brain 
to increase energy expenditure [27], and adiponectin stimu-
lates FFA oxidation [28] and may enhance clearance of FFA. 
This may contribute to normal FFA levels in patients with CF 
and insulin deficiency. Although not directly estimated in our 
study subjects, increased resting energy expenditure in our 
patients with CF is likely. Given that adiponectin increases 
insulin sensitivity by stimulating FFA oxidation, the high ad-
iponectin could explain the “unexpectedly” normal insulin 
sensitivity. At low insulin concentrations, glucose disappear-
ance rates correlate with adiponectin in controls and in pa-
tients with type1 diabetes [16], but whether the same is true 
for glucose and FFA disappearance in patients with CF has not 
yet been specifically studied.
Distinct patient and control populations most likely ex-
plain different findings regarding adiponectin in CF studies, 
limited capacity to adapt appropriately to an increased insulin 
resistance, OGT may rapidly change over time, more than in 
healthy individuals. Insulin resistance is to be expected in 
the context of inflammation and low muscle mass; it may 
be found by hyperinsulinemic glucose clamp studies where 
skeletal muscle is the main target for high rates of glucose 
uptake. ISI
comp
 calculated by data obtained during OGTTs 
addresses more closely the importance of insulin sensitivity 
at ambient insulin levels, while the hyperinsulinemic clamp 
method preferentially addresses effects of high dose insulin 
on skeletal muscle. Normal insulin sensitivity is also in line 
with clinical observations in patients with CFRD, who usually 
need less insulin than patients with type 2 diabetes for blood 
glucose control. However, exogenous insulin requirements 
         
** **
 ** ** *  
* 
**
* 
**
 ** ** *  
** 
Figure 2: Total adiponectin, its high molecular weight-form and 
leptin.
Individual values, median and interquartile ranges are shown. *p 
< 0.05, **p < 0.01, ***p < 0.001 for the comparison controls vs. CF 
total/CF no CFRD/CF CFRD.
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insulin injections may not be the most appropriate first line 
treatment, rather, we strongly advocate - independently of 
fasting glucose and A1c values, close clinical observations 
in individuals with CF as important bases to propose food-
related (preprandial injection) insulin therapy.
Conclusions
In summary, we conclude that despite markedly impaired 
insulin secretion, oral glucose suppressed FFA to a similar ex-
tent in patients with CF as in healthy subjects. Residual insu-
lin in the face of increased energy expenditure (and possibly 
adiponectin-enhanced-FFA oxidation) and apparently normal 
insulin sensitivity appears to be sufficient for maintaining FFA 
homeostasis in patients with CF. 
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